Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.44 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 4/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499165 | 1.00 | GPR132 (0.50) | GPR132PPARGGAARAB9ACMKLR2 | |
| SCHEMBL3500992 | 0.93 | GPR132 (0.59) | GPR132PPARGCMKLR2CMKLR1GPR34 | |
| SCHEMBL3500990 | 0.93 | GPR132 (0.59) | GPR132PPARGCMKLR2CMKLR1GPR34 | |
| SCHEMBL3500418 | 0.92 | PPARG (0.48) | GPR132PPARGGAARAB9ALTA4H | |
| SCHEMBL3500421 | 0.92 | PPARG (0.48) | GPR132PPARGGAARAB9ALTA4H | |
| SCHEMBL3497391 | 0.89 | GPR34 (0.55) | PPARGGAARAB9ALTA4HYAP1 | |
| SCHEMBL3497393 | 0.89 | GPR34 (0.55) | PPARGGAARAB9ALTA4HYAP1 | |
| SCHEMBL3502020 | 0.86 | RAB9A (0.48) | PPARGGAARAB9ALTA4HYAP1 | |
| SCHEMBL3498073 | 0.86 | CDK2 (0.54) | PPARGGAARAB9ALTA4HYAP1 | |
| SCHEMBL3502021 | 0.86 | RAB9A (0.48) | PPARGGAARAB9ALTA4HYAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | GPR132 13/4885PPARG 189/4885GAA 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.